SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Pablo Neruda — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPablo Neruda
Date of birth1904-07-12
IdentifiersMRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976
Document date1971-07-13
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week review on apalutamide and leuprolide. [S]

History of Present Illness

Mr. Neruda returns four weeks after starting apalutamide and three weeks after his first leuprolide injection, with a professional Spanish interpreter. The right hip pain has eased to 2 of 10 and no longer wakes him; he takes acetaminophen once a day at most. He gets up to pass urine twice a night instead of three times. Mild hot flashes began last week. His energy is a little lower in the afternoons. He has had no rash, falls, dizziness, leg weakness or numbness. He saw his dentist a week ago; no dental work is needed. He takes vitamin D every day. The germline test result came back last week: no harmful variant was found. He had his radiotherapy planning visit, and treatment starts in two weeks. Before radiotherapy, his bowels are regular, once a day, with no bleeding. [S]

ElementDetail
TreatmentApalutamide four weeks; leuprolide three weeks ago
SymptomsPain 2 of 10; nocturia twice; mild hot flashes; no rash or falls
Results since last visitGermline panel negative; dental examination clear
Next stepRadiotherapy to the prostate starts in two weeks

Review of Systems

SystemResultFinding
ConstitutionalPositiveSlightly lower afternoon energy; weight stable
EndocrinePositiveMild hot flashes for a week
MusculoskeletalPositiveRight hip pain 2 of 10
IntegumentaryNegativeNo rash or itch
GastrointestinalNegativeBowels regular once a day; no bleeding
NeurologicalNegativeNo weakness, numbness or dizziness

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route1966-04-06 to 1971-07-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1971-07-13activeS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route1971-06-01 to 1971-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route1971-06-15activeS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeksOne injection every twelve weeksIntramuscular route1971-06-22activeS
Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route1971-06-15activeS
Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivationOne injection every six monthsSubcutaneous route1971-07-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1971-07-13Body height178cmS
1971-07-13Body weight92.8kgS
1971-07-13Body mass index (BMI) [Ratio]29.3kg/m2S
1971-07-13Systolic blood pressure152mm[Hg]S
1971-07-13Diastolic blood pressure90mm[Hg]S
1971-07-13Heart rate76/minS
1971-07-13Respiratory rate14/minS
1971-07-13Body temperature36.6CelS
1971-07-13Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1971-07-13Prostate specific Ag [Mass/volume] in Serum or Plasma6.2ng/mL<=4 ng/mLHighS
1971-07-13Testosterone [Mass/volume] in Serum or Plasma22ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
1971-07-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1971-07-13Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1971-07-13Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
1971-07-13Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
1971-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-07-13Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1971-07-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L7-55 U/LNormalS
1971-07-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
1971-07-13Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma141U/L40-129 U/LHighS
1971-07-13Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
1971-07-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma28ng/mL30-100 ng/mLLowS
1971-07-13Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
1971-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1971-07-13International Prostate Symptom Score [IPSS]14{score}S
1971-07-13Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S

Physical Exam

Vital signs recorded on 1971-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; walks without favoring the right hip
CardiovascularRegular rhythm; blood pressure 152/90 mm Hg on repeat; no ankle swelling
SkinNo rash
NeurologicalStrength and sensation normal in both legs

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA on androgen deprivationEvery 3 to 6 months; an early value here for symptomatic diseaseCompleted today6.2 ng/mL, down from 46.8
LaboratoryTestosteroneEvery 3 to 6 months on androgen deprivation (target below 50 ng/dL)Completed today22 ng/dL, castrate
LaboratoryChemistry with calcium and alkaline phosphataseBefore denosumab; periodically in metastatic diseaseCompleted todayCalcium 9.3 mg/dL; creatinine 0.98 mg/dL; ALT 25 U/L; alkaline phosphatase 141 U/L, falling
Laboratory25-hydroxyvitamin DBefore a bone-protective drug and periodicallyCompleted today28 ng/mL, up from 22
LaboratoryTSH on apalutamidePeriodically, about every four monthsCompleted today2.4 mIU/L, the first value, four weeks into treatment
LaboratoryBaseline TSH before apalutamide missedBefore starting apalutamideDeferredOrdered at the last visit but not drawn, a deviation from the protocol: the order was not on the laboratory requisition sent with the germline sample. Today's value is normal, so a pre-existing thyroid problem is unlikely and no harm has resulted, but a true baseline is lost. Corrective action: the apalutamide start checklist now includes TSH, drawn with the first prescription
LaboratoryHemoglobin A1c and lipid panelBaseline and yearly on androgen deprivationUp to dateBaseline six weeks ago; A1c again at three months
ImagingBone density (DXA)Every 1 to 2 years on androgen deprivationUp to dateBaseline four weeks ago
ExaminationBlood pressure and cardiovascular assessmentEvery visit on androgen deprivationCompleted today152/90 mm Hg, above goal; amlodipine raised
ExaminationNeurological check for spinal cord compressionEvery visit with spinal metastasesCompleted todayNormal
SurveyDistress and depression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 1
SurveyPain scoreEvery visit with symptomatic metastasesCompleted today2 of 10, down from 6
SurveyUrinary symptoms (IPSS)Every follow-up visitCompleted todayIPSS 14, down from 17
SurveyBowel function before radiotherapyBaseline before radiotherapyCompleted todayRegular once a day; no bleeding
Medication safetyRash on apalutamideEvery visit on androgen deprivationCompleted todayNone
Medication safetyFalls on apalutamideEvery visit on androgen deprivationCompleted todayNo falls or dizziness
Medication safetyHot flashes and fatigueEvery visit on androgen deprivationCompleted todayMild; no treatment wanted
Medication safetyDenosumab: calcium, vitamin D and dental check before the first doseBefore each doseCompleted todayCalcium normal; vitamin D rising; dental examination clear a week ago; first dose given today
ReferralGermline testing resultOnceCompleted todayNo pathogenic variant on a multigene panel including BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13 and the mismatch repair genes
ReferralSomatic tumor testingOnce, for metastatic diseaseOrderedSent on the biopsy tissue; pending
ReferralRadiotherapy to the prostateOnceOrderedPlanning done; 20 fractions start in two weeks
SurveyCognitionPeriodically on androgen deprivationDueMini-Cog at the annual wellness visit
Self-managementPhysical activity and calcium intakeEvery visitCompleted todayWalking most afternoons; light resistance exercise started; calcium from food

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)

Follow-up: Radiotherapy from two weeks' time. Home blood pressure readings through the portal in two weeks. Review in nine weeks, at three months, with PSA, testosterone, blood count, chemistry, TSH and hemoglobin A1c, and the second leuprolide injection. Next scheduled visit 1971-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. [S]